Article

Real World Predictors of Response and 24-month survival in high-grade TP53-mutated Myeloid Neoplasms

2024-03-13

Abstract excerpt

Current therapies for high-grade TP53-mutated myeloid neoplasms (≥ 10% blasts) do not offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority who achieve a complete response to first line therapy (CR1). To identify reliable pre-therapy predictors of response and outcomes, we assembled a cohort of 234 individuals with well-annotated clinical, molecular and pathology data, eva...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9bf94e3f-5646-500c-be03-550daad7c3ac
DOI: 10.1101/2024.03.11.24303995

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Real World Predictors of Response and 24-month survival in high-grade TP53-mutated Myeloid NeoplasmsDOI 10.1101/2024.03.11.24303995Read

Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.Semantic proximity Read

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasmsSemantic proximity Read

Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion.Semantic proximity Read

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read

The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations.Semantic proximity Read

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxSemantic proximity Read

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read

Navigating prognostic stratification and approach to TP53 -mutated myeloid neoplasms.Semantic proximity Read

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.Semantic proximity Read

TP53 in AML and MDS: The new (old) kid on the block.Semantic proximity Read

Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.Semantic proximity Read

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.Semantic proximity Read